Matthew E. Ros is listed as a director on 1 SEC Form D filing by 1 issuer in Aug 2026: Jasper Therapeutics, Inc. (Redwood City, CA — biotechnology — 2026; $132M reported sold to 40 investors).
What this means One deal on file with the SEC, filed Aug 2026. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Gregory F. Keenan (1 shared filing), Herb Cross (1 shared filing), Jeet Mahal (1 shared filing), Judith Shizuru (1 shared filing), Kurt von Emster (1 shared filing) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Matthew. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for Matthew E. Ros and found 2 differences: Same name, different state: "Matthew Ros" (PA) is a separate record; Same name, different state: "Matthew Ros" (MA) is a separate record.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.